Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

Dear Common Dreams Readers:
Corporations and billionaires have their own media. Shouldn't we? When you “follow the money” that funds our independent journalism, it all leads back to this: people like you. Our supporters are what allows us to produce journalism in the public interest that is beholden only to people, our planet, and the common good. Please support our Mid-Year Campaign so that we always have a newsroom for the people that is funded by the people. Thank you for your support. --Jon Queally, managing editor

Join the small group of generous readers who donate, keeping Common Dreams free for millions of people each year. Without your help, we won’t survive.

FDA chief speaks at a congressional hearing

Dr. Janet Woodcock, acting commissioner of the Food and Drug Administration, prepares to testify during a Senate Appropriations Subcommittee hearing on June 10, 2021. (Photo: Bill Clark/CQ-Roll Call, Inc. via Getty Images)

After Months of Controversy, FDA Chief Requests Probe of Alzheimer's Drug Approval

Public Citizen, which called for the FDA acting commissioner "to immediately resign or be removed" over the "reckless and inexcusable" drug approval, welcomed her "belated" request.

Jessica Corbett

Public health advocates and other critics of the Food and Drug Administration's June decision to approve the first new medication for Alzheimer's disease in nearly two decades welcomed the acting commissioner's Friday call for an independent investigation into the agency's review of the questionably effective drug—including staff contact with its developer, Biogen.

The probe request from Dr. Janet Woodcock, the FDA's acting commissioner, came just a day after the agency narrowed its recommendation about which patients are given Biogen's drug aducanumab, known by the brand name Aduhelm. It also follows an exposé in STAT revealing that "FDA officials worked hand in hand with Biogen executives to get the drug on the market."

Public Citizen—a consumer advocacy group that has repeatedly called for Woodcock "to immediately resign or be removed" over the "reckless and inexcusable" approval of the drug—noted the development on Twitter and declared, "The public deserves transparency."

In her Friday letter to Christi Grimm, acting inspector general for the U.S. Department of Health and Human Services (HHS), Woodcock acknowledged that "there has been significant attention and controversy surrounding the process for review" of the monthly intravenous infusion with a $56,000 annual price tag.

Given growing concerns among advocates, lawmakers, and doctors—including multiple members of an FDA advisory panel who resigned in protest—Woodcock requested that HHS's Office of Inspector General conduct "an independent review and assessment of interactions between representatives of Biogen and the FDA during the process" that led to the agency's "accelerated approval" of Aduhelm.

Woodcock noted concerns "regarding contacts between representatives from Biogen and FDA during the review process, including some that may have occurred outside of the formal correspondence process," and said that for the sake of public confidence in the agency, it is critical to determine if any interactions "were inconsistent with FDA policies and procedures."

Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School and Brigham and Women's Hospital, is one of three experts who quit an FDA advisory panel last month over Aduhelm's approval.

Kesselheim expressed support for a probe and told the New York Times that "it's really important that an investigation happen publicly and quickly so that we find answers to some of the many outstanding questions swirling around this decision."

Dr. Michael Carome, director of Public Citizen's Health Research Group, also welcomed Woodcock's "belated request for an independent IG investigation of her agency's inappropriately close collaboration with Biogen," pointing out that his group had called for a probe months ago.

"Such an investigation must be broad and determine when Dr. Woodcock first became aware of this collaboration and whether she ever specifically endorsed or facilitated it in any way," he said in a statement Friday.

Carome continued:

The IG also must examine how Dr. Woodcock fostered a culture within the FDA's Center for Drug Evaluation and Research that permitted and encouraged such an inappropriate collaboration with regulated industry. Under her leadership over the past three decades, the relationship between the FDA and the pharmaceutical industry has grown ever cozier—resulting in regulatory capture of the agency by industry.

It is also imperative that Congress proceed expeditiously with its own announced investigation of the FDA-Biogen collaboration to ensure a thorough assessment and public airing of the circumstances that lead to the FDA's reckless and inexcusable decision to approve aducanumab.

Alexander Gaffney, head of research at Politico's AgencyIQ—a division focused on the regulatory environment, particularly the FDA—suggested the agency "might think they have a better chance with OIG than with Congress. (But the risk is that what OIG finds leads to more congressional interest)."

STAT reported that "one former FDA official said that an investigation could actually help distance Woodcock from the controversial Aduhelm decision. The longtime agency veteran is currently its acting commissioner, but she is a leading contender to be nominated for the full role. The official pointed out that even though Woodcock was not involved in the approval decision, it was made by people she had elevated to decision-making roles."

As the medical news outlet explained:

Inspector general investigations are among the most serious types of civil investigations that can be conducted into a federal agency. The inspector general's office typically has broad power to subpoena internal FDA documents and to conduct interviews under oath. The OIG can also refer potential criminal violations to the Department of Justice. However, no allegations of criminal conduct have been made against the FDA.

It is rare for the OIG to investigate the FDA, and even more exceptional for it to investigate an individual drug approval decision, according to STAT's review of public records. The inspector general is currently reviewing a number of FDA programs, like its systems for monitoring the safety of medical devices, though the majority of those inquiries are audits and evaluations, less serious forms of investigations.

Although an HHS investigation is not yet guaranteed, Dana Conti, a spokesperson for Biogen, told the Times that the company "will, of course, cooperate with any inquiry in connection with a possible review of the regulatory process."

CNBC reported that "shares of Biogen fell by more than 3% after the announcement" of Woodcock's request. Alarm over the FDA's approval of the drug stems from not only potentially problematic interactions between the agency and Biogen but also uncertainty over the effectiveness of Aduhelm.

"Recognizing that clinical trials of the drug had provided incomplete evidence to demonstrate effectiveness, the FDA granted approval for the drug to be used but required Biogen to conduct a new clinical trial," the Times explained last month. "If the new trial, called a Phase 4 trial, fails to show the drug is effective, the FDA can—but is not required to—rescind its approval."


Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.

"I'm sure this will be all over the corporate media, right?"
That’s what one longtime Common Dreams reader said yesterday after the newsroom reported on new research showing how corporate price gouging surged to a nearly 70-year high in 2021. While major broadcasters, newspapers, and other outlets continue to carry water for their corporate advertisers when they report on issues like inflation, economic inequality, and the climate emergency, our independence empowers us to provide you stories and perspectives that powerful interests don’t want you to have. But this independence is only possible because of support from readers like you. You make the difference. If our support dries up, so will we. Our crucial Mid-Year Campaign is now underway and we are in emergency mode to make sure we raise the necessary funds so that every day we can bring you the stories that corporate, for-profit outlets ignore and neglect. Please, if you can, support Common Dreams today.

 

Right-Wing Justices Should Be Impeached for Lying Under Oath, Says Ocasio-Cortez

"We have a responsibility to protect our democracy," said the New York Democrat. "That includes holding those in power who violate the law accountable."

Kenny Stancil ·


'Infuriating': Biden Rebuked for Continued Opposition to Supreme Court Expansion

"What does Biden 'agree' with doing?" Mehdi Hasan asked. "What does the leader of this country want to do to stop the increasingly fascistic assault on our democratic institutions and basic rights?"

Kenny Stancil ·


'We Need Action': Biden, Democrats Urged to Protect Abortion Access in Post-Roe US

"The Supreme Court doesn't get the final say on abortion," Sens. Elizabeth Warren and Tina Smith wrote in a new op-ed.

Kenny Stancil ·


Motorist 'Tried to Murder' Abortion Rights Advocates at Iowa Protest, Witnesses Say

Although one witness said the driver went "out of his way" to hit pro-choice protestors in the street, Cedar Rapids police declined to make an arrest.

Kenny Stancil ·


'A Hate Crime': Oslo Pride Parade Canceled After Deadly Shooting at Gay Bar

A 42-year-old gunman has been charged with terrorism following what Norway's prime minister called a "terrible and deeply shocking attack on innocent people."

Kenny Stancil ·

Common Dreams Logo